NEUROGENE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.96 USD | +0.30% |
|
-1.74% | +54.59% |
| 03-22 | North American Morning Briefing : Stocks Struggle After New Records | DJ |
| 03-21 | William Blair Initiates Neurogene With Outperform Rating | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 248.5 | 385.1 | - | - |
| Enterprise Value (EV) 1 | 51.47 | 57.98 | -116 | 385.1 |
| P/E ratio | -2.49 x | -8.28 x | -8.75 x | -6.97 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | -0.99 x | -0.84 x | 1.53 x | -4.64 x |
| FCF Yield | -101% | -119% | 65.5% | -21.6% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 12,824 | 12,853 | - | - |
| Reference price 2 | 19.38 | 29.96 | 29.96 | 29.96 |
| Announcement Date | 24-03-18 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -55.58 | -65.24 | -78.36 | -89 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -36.32 | -59.24 | -75.62 | -88.86 |
| Net income 1 | -55.19 | -36.32 | -66.89 | -74.35 | -86.1 |
| Net margin | - | - | - | - | - |
| EPS 2 | -10.58 | -7.798 | -3.620 | -3.422 | -4.300 |
| Free Cash Flow 1 | - | -51.74 | -69 | -76 | -83 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 23-11-08 | 24-03-18 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -14.73 | -15.32 | -15.95 | -16.64 | -17.37 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 2.383 | -13.81 | -14.42 | -15.12 | -15.89 |
| Net income 1 | 2.383 | -17.13 | -15.73 | -16.74 | -17.66 |
| Net margin | - | - | - | - | - |
| EPS 2 | - | -0.9950 | -0.9067 | -0.9533 | -0.8567 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 24-03-18 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 197 | 327 | 501 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -51.7 | -69 | -76 | -83 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.32 | 1.5 | 1.1 | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 23-11-08 | 24-03-18 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
29.96
USD
Average target price
53.33
USD
Spread / Average Target
+78.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +54.59% | 385M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NGNE Stock
- Financials Neurogene Inc.
